George Eldridge is the Chief Financial Officer at Abcuro. He brings over 30 years of experience in fundraising, taking companies public, facilitating mergers and acquisitions, and establishing critical financial operations. Most recently, George served as Chief Financial Officer at Aerovate Therapeutics guiding the company though its successful initial public offering (IPO) in 2021 and subsequent reverse merger with Jade Biosciences in 2025. Before this, he served as Senior Vice President and Chief Financial Officer of Proteon Therapeutics. Earlier, George spent four years as a consultant to various companies in the biotechnology industry, acting as a Chief Financial Officer and providing advisory services. George has also held Chief Financial Officer roles at Targanta Therapeutics, until its acquisition in 2009 by The Medicines Company, Therion Biologics, Curis (previously Ontogeny, Inc.) and Boston Life Sciences. Earlier in his career, George was an investment banker at Kidder Peabody & Co, Inc. He holds a BA from Dartmouth College and an MBA from the University of Chicago, Booth School of Business.

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.